Precision Neuroscience Appoints Two New Executives
The brain-computer interface firm taps industry veterans to lead its transition toward commercial product availability.
Updated on Oct. 15, 2026 in People
Live Poll
Do you trust that new medical technology companies will successfully bring their products to patients?
Precision Neuroscience has appointed Konstantinos Alataris as president and Katherine Neuenfeldt as senior vice president of commercial strategies. These leadership changes are intended to help the company shift from technology demonstration to bringing its medical devices to market.
Why it matters
The company is aiming to scale its brain-computer interface technology for wider medical use. This transition follows significant capital investment and regulatory progress for the firm's neural recording hardware.
Precision Neuroscience has secured $430 million in total funding since its 2021 founding, including a $250 million Series D round. The firm has also successfully completed over 100 patient procedures across 18 separate medical institutions.
The players
Konstantinos Alataris
He is the new president of Precision Neuroscience who previously served on the company's board of directors.
Katherine Neuenfeldt
She is the new senior vice president of commercial strategies tasked with building the firm's commercial teams and market access.
Precision Neuroscience
This is a medical technology company headquartered in New York that specializes in brain-computer interface devices.
The details
Konstantinos Alataris, who served on the board since May 2025, joins the executive team alongside Katherine Neuenfeldt. Neuenfeldt will oversee market access, reimbursement, and the expansion of the commercial team, supporting the rollout of technology like the FDA-cleared Layer 7 cortical surface array.
Timeline
2021: Precision Neuroscience was founded.
May 2025: Alataris joined the board of directors.
October 15, 2026: Precision Neuroscience announced the new executive appointments.
Market Landscape
Precision Neuroscience is aggressively positioning itself to scale its brain-computer interface technology as it moves past the Layer 7 cortical surface array's initial regulatory hurdles. These executive additions reflect a broader industry trend of shifting from experimental research to sustainable commercial operation.
Patients and healthcare providers should anticipate potential changes in how this brain-interface technology is reimbursed and made accessible within the hospital system. These strategic hires suggest the company is preparing to standardize its service model for more widespread clinical integration.
The takeaway
Precision Neuroscience is signaling a shift toward operational maturity as it attempts to bring complex neuro-tech to the clinical market. Its ability to navigate reimbursement hurdles will determine how quickly this technology reaches patients in need.
Further reading
Learn more about the latest leadership changes in the industry at United States People.
More information
For more information on the company, visit the Precision Neuroscience corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that new medical technology companies will successfully bring their products to patients?
